Technologies for translational imaging using generators in oncology

Recent Patents on Anti-Cancer Drug Discovery

Volumn 2, Issue 3, 2007, Pages 251-258

  Schechter, Naomi R ^a   Yang, David J ^b   Azhdarinia, Ali ^b   Chanda, Mithu ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Molecular imaging; PET; SPECT

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 3' FLUOROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; BROMINE 77; CARBON 11; CHELATING AGENT; CISPLATIN; CYCLAM TYROSINE GA 68; ERLOTINIB; ETIDRONIC ACID RE 188; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GEFITINIB; GLIPIZIDE; GLUCOSAMINE; GUANINE; IMATINIB; IODINE 131; METRONIDAZOLE; MOLYBDENUM 99; PENTETATE TECHNETIUM TC 99M; PENTETIC ACID; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM 188; SUCCIMER; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER RESEARCH; CANCER SCINTISCANNING; CANCER THERAPY; CARCINOID; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; ECHOGRAPHY; HUMAN; HYPOXIA; MALIGNANT NEOPLASTIC DISEASE; METABOLIC PARAMETERS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATENT; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION EXPOSURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT PLANNING; TREATMENT RESPONSE;

ANIMALS; DIAGNOSTIC IMAGING; FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; HUMANS; NEOPLASMS; PATENTS AS TOPIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 36749071688     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489207782497253     Document Type: Article

References (55)

1. 99mTc-ethylenedicysteine-colchicine for evaluation of antiangiogenic effect. Anticancer Drugs 1999; 10: 685-92.
2. 99mTc-EC-endostatin. Cancer Mother Radiopharm 2002; 17: 23345.
3. 99mTe-labeled celebrex. Anti-Cancer Drugs 2004; 15: 255-63.
4. Ito M, Yang DJ, Mawlawi O, et al. PET and planar imaging of tumor hypoxia with labeled metronidazole. Acad Radjol 2006; 13(5): 598-609.
5. Ohtsuki K, Akashi K, Aoka Y, et al. Technotium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis. Eur J Nucl Med 1999; 26(10): 1251-58.
6. 99mTc annexin V for in vivo imaging of apoptusis during cardiac allograft rejection. J Thorac Cardiovasc Sing 1998; 116: 844-53.
7. 3H]thymidine, and gallium-67. J Nucl Med 1991; 32: 2118-23.
8. 99mTc-ethylcnedicysteine-C225 monoclonal antibody. Anticancer Drugs 2003; 14: 49-56.
9. Yoo IeR, Park HJ, Hyun J, et al. Two cases of pulmonary paragonimiasis on FDG-PET CT imaging. Ann Nucl Med 2006; 20(4): 311-5.
10. Wyss MT, Spaeth N, Biollaz G, et al. Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP(L19), a marker of angiogenesis. J Nucl Med 2007; 48(4): 608-14.
11. Personal Communication, Osama Malawi, Ph.D., Assoc. Professor, Imaging Physics, M. D. Anderson Cancer Center, 2007.
12. Hofmann M, Maecke H, Burner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28(12): 1751-7.
13. Caner EP, Casali C, Desenfant A, et al. Kinetic characterization of CMD-A2-Gd-DOTA as an intravascular contrast agent for myocardial perfusion measurement with MRI. Magn Reson Med 2000 43(3): 403-9.
14. Van Nerom CG, Bormans GM, De Roo MJ, Verbruggen AM. First experience in healthy volunteers with technetium-99m L, L-ethylenedicysteine, a new renal imaging agent. Eur J Nucl Med 1993; 20: 738-46.
15. 99mTc-MAG3 dynamic scintigraphy. Magn Reson Imaging 1994; 12(3):413-19.
16. Wu HC, Chang CH, Lai MM, Lin CC, Lee CC, Kan A. Using Tc-99m DMSA renal cortex scan to detect renal damage in women with type 2 diabetes. J Diabetes Complicat 2003; 17:297-300.
17. Anderson CJ, John CS, Li YJ, et al. N, N′-ethylene-di-L-cysteine (EC) complexes of Ga(III) and In(III): molecular modeling, thermodynamic stability and in vivo studies. Nucl Med Biol 1995; 22:165-73,
18. Sun Y, Anderson CJ, Pajeau TS, et al. Indium, (III) and gallium (III) complexes of bis(aminoethanethiol) ligands with different denticities: stabilities, molecular modeling, and in vivo behavior. J Med Chem 1996; 39: 458-70.
19. Zheng YY, Saluja S, Yap GP, Blumenstein M, Rheingold AL, Francesconi LC. Gallium and indium complexes of Bis(amino thiol) (N(2)S(2)) Ligands. Inorg Chem 1996; 35: 6656-66.
20. Yang DJ, Azhdarinia A, Kim EE. Tumor specific imaging using Tc-99m and Ga-68 labeled radiopharmaceuticals. Curr Med Iniag Rev 2005; 1: 25-34.
21. Li S, Liu J, Zhang H, Tian M, Wang J, Zheng X. Rhenium-188 HEDP to treat painful bone metastases. Clin Nucl Med 2001; 26(11): 919-22.
22. Knapp FF Jr, Beets AL, Guhlke S, et al. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-189 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. Anticancer Res 1997; 17(3B): 1783-95.
23. Azhdarinia A, Yang DJ, Yu D-F, et al. Regional radiochemothcrapy using in situ hydrogel. Pharm Res 2005; 22(5): 776-83.
24. 99mTc-EC-annexin V. Cancer Biother Radiopharm 2001; 16: 73-83.
25. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51: S368-76.
26. Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled fluoro-erythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995; 194: 795-800.
27. 131I]iodoerythronitroimidazole. J Drug Targeting 1996; 4: 31-39.
28. 99mTc-labeled metronidazole. Pharm Res 1999; 16(5): 743-50.
29. 99mTc-metronidazole. Stroke 2003; 34: 982-86.
30. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. J Biol Chem 1991; 266: 4706-12.
31. Wells L, Gan Y, Mahoney JA, et al. Dynamic O-glycosylation of nuclear and cytosolic proteins: further characterization of the nucleocytoplasmic beta-N-acetylglucosaminidase, O-GlcNAcase. J Biol Chem 2002; 277: 1755-61.
32. Pal S, Claffey KP, Cohen HT, Mukhopadhyay D. Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. J Biol Chem 1998; 273: 26277-80.
33. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001; 188: 143-60.
34. 99mTc ECDG targeted at the multifunctional glucose transport system: feasibility study with rodents. Radiology 2003; 226: 465-73.
35. 99mTc-ethylenedicysteine-glucosamine. Cancer Biother Radiopharm 2004; 19(4): 444-58.
36. Goethals P, Eijkeren MV, Lodewyck W, Dams R. Measurement of [methyl-carbon-11] thymidine and its metabolites in head and neck tumors. J Nucl Med 1995; 36: 880-82.
37. Tjuvajev J, Macapinlac HA, Daghighian F, et al. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J Nucl Med 1994; 35: 1407-17.
38. 18F-5-flourodeoxyuridine in animals. Eur J Nucl Med 1983; 8:258-61.
39. 18F]fluoroethyluracil. J Pharm Sci 1996; 85: 339-44.
40. 18F]fluoroethyluracil. J Pharm Sci 1996; 85: 339-44.
41. 18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003; 30: 988-94.
42. 99mTc-EC-Guanine: Synthesis, biodistribution and tumor imaging in animals. Pharm Res 2005; 22(9): 1471-9.
43. Gong J, Yang DJ, Kohanim S, Humphreys R, Broemeling L, Kurzrock R. Novel in vivo imaging demonstrates upregulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. Mol Cancer Ther 2006; 5(12): 2991-3000.
44. Jager PL, Plaat BE, de Vries EG, et al. Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity. Clin Cancer Res 2000; 6: 2252-9.
45. McConathy J, Martarello L, Malveaux EJ, et al. Synthesis and evaluation of 2-amino-4-[(18)F]fluoro-2-methylbutanoic acid (FAMB): relationship of amino acid transport to tumor imaging properties of branched fluorinated amino acids. Nucl Med Biol 2003; 30: 477-90.
46. Karacaliogla AO, Yang DJ, Azhdarima A, et al. Radiolabeled L-lysine for tumor imaging. Acad Radiol 2006; 13(11): 1327-37.
47. Zaidi H, Koral KF. Scatter modelling and compensation in emission tomography. Eur J Nucl Med Mol Imaging 2004; 31: 761-782.
48. Tagliabue L, Schillaci O. SPECT/CT in oncology: the fusion of two imaging modalities is a new standard of care. Q J Nucl Med Mol Imaging 2007; 51(4): 285-9.
49. Nakahara T, Shigematsu N, Fujii M, et al. Value of CT thallium-201 SPECT fusion imaging over SPECT alone for detection and localization of nasopharyngeal and maxillary cancers. AJR Am J Roentgenol 2006; 187(3): 825-9.
50. Kramer EL, Noz ME. CT-SPECT fusion for analysis of radiolabeled antibodies: applications in gastrointestinal and lung carcinoma. Int J Rad Appl Instrum B 1991; 18(1): 27-42.
51. Bailey DL, Roach PJ, Bailey EA, Hewlett J, Keijzers R. Development of a cost-effective modular SPECT/CT scanner. Eur J Nucl Med Mol Imaging 2007; 34(9): 1415-26.
52. Roach PJ, Schembri GP, Ho Shon IA, Bailey EA, Bailey DL. SPECT/CT imaging using a spiral CT scanner for anatomical localization: Impact on diagnostic accuracy and reporter confidence in clinical practice. Nucl Med Common 2006; 27(12): 977-87.
53. Hillel PG, van Beek EJ, Taylor C, et al. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours. Clin Radiol 2006; 61(7): 579-87.
54. Achilefu, S.I., Rajagopalan, R., Dorshow, R.B., Bugaj, J.E., Periasamy, M.P.: US20077198778 (2007).
55. Artemov, D., Kato, Y.: WO07028141 (2007).